Charles Schwab Investment Management Inc. Acquires 9,000 Shares of Rezolute, Inc. (NASDAQ:RZLT)

Charles Schwab Investment Management Inc. raised its holdings in shares of Rezolute, Inc. (NASDAQ:RZLT) by 65.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 22,757 shares of the company’s stock after acquiring an additional 9,000 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Rezolute were worth $112,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently modified their holdings of RZLT. JPMorgan Chase & Co. bought a new position in Rezolute in the 3rd quarter worth $42,000. MML Investors Services LLC bought a new stake in Rezolute during the third quarter valued at about $57,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Rezolute in the third quarter worth about $65,000. Virtu Financial LLC raised its stake in shares of Rezolute by 58.0% in the third quarter. Virtu Financial LLC now owns 26,026 shares of the company’s stock worth $126,000 after buying an additional 9,551 shares during the period. Finally, Jacobs Levy Equity Management Inc. bought a new position in shares of Rezolute in the third quarter worth about $239,000. Institutional investors own 82.97% of the company’s stock.

Insider Buying and Selling

In other Rezolute news, CFO Daron Evans purchased 10,000 shares of Rezolute stock in a transaction that occurred on Wednesday, March 26th. The shares were bought at an average price of $2.89 per share, for a total transaction of $28,900.00. Following the completion of the transaction, the chief financial officer now owns 237,900 shares of the company’s stock, valued at approximately $687,531. This trade represents a 4.39 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Nevan C. Elam purchased 12,302 shares of the firm’s stock in a transaction that occurred on Thursday, March 27th. The shares were acquired at an average cost of $2.85 per share, for a total transaction of $35,060.70. Following the purchase, the chief executive officer now owns 224,119 shares of the company’s stock, valued at $638,739.15. This represents a 5.81 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have bought 39,060 shares of company stock worth $130,694. Corporate insiders own 18.39% of the company’s stock.

Rezolute Stock Performance

RZLT stock opened at $2.92 on Wednesday. The company’s fifty day moving average price is $4.18 and its 200-day moving average price is $4.72. Rezolute, Inc. has a one year low of $2.22 and a one year high of $6.19. The company has a market capitalization of $176.76 million, a PE ratio of -2.39 and a beta of 0.95.

Rezolute (NASDAQ:RZLT) last announced its quarterly earnings results on Wednesday, February 12th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.11. On average, research analysts predict that Rezolute, Inc. will post -0.93 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on RZLT. HC Wainwright reissued a “buy” rating and issued a $14.00 target price on shares of Rezolute in a report on Thursday, February 13th. Guggenheim reissued a “buy” rating on shares of Rezolute in a research note on Monday, February 10th. JMP Securities lifted their target price on shares of Rezolute from $8.00 to $9.00 and gave the company a “market outperform” rating in a research note on Thursday, February 13th. Finally, Craig Hallum upgraded Rezolute to a “strong-buy” rating in a research note on Tuesday, February 4th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $24.38.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.